Palbociclib
Fulvestrant
Tianjin Medical University Cancer Institute and HospitalSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the Fulvestrant cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FULVESTRANT Olema Pharmaceuticals, Inc. | Phase 1 | CC |
op-3136 Olema Pharmaceuticals, Inc. | Phase 1 | CC |
Palazestrant Olema Pharmaceuticals, Inc. | Phase 1 | CC |
Same molecule, other indications
Palbociclib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →